• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    April 17, 2023 - FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation

    4/17/23 1:02:15 PM ET
    $GMDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GMDA alert in real time by email
    For Immediate Release:
    April 17, 2023

    Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product is intended for use in adults and pediatric patients 12 years and older with blood cancers planned for umbilical cord blood transplantation following a myeloablative conditioning regimen (treatment such as radiation or chemotherapy). 

    “Today’s approval is an important advance in cell therapy treatment in patients with blood cancers,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “Hastening the return of the body’s white blood cells can reduce the possibility of serious or overwhelming infection associated with stem cell transplantation. This approval reflects the FDA’s continued commitment to supporting development of innovative therapies for life-threatening cancers.”

    Blood cancers are a form of cancer caused by uncontrolled growth of cells in the blood, disrupting the ability of blood cells to perform their normal functions. This abnormal cell growth often begins in the bone marrow, which is made up of stem cells that form into different types of blood cells with specific functions in the body. Blood cancers represent about 10% of all cases of cancer each year in the U.S. Blood cancers can be fatal, with varying survival rates based on multiple factors including the specific type of blood cancer diagnosed. This type of cancer can also cause serious and damaging effects to the body and lead to symptoms such as fatigue, bone and joint pain, night sweats, infections, weakness, weight loss and fever. 

    Stem cell transplantation is a common treatment for blood cancers. It involves putting healthy stem cells into the body to help restore the normal production and function of blood cells. One source of healthy stem cells is umbilical cord blood. Generally, before receiving this kind of transplant, the patient will undergo a course of treatments to remove their own stem cells and prepare the body for the new stem cells. This process may include undergoing therapies such as radiation or chemotherapy, both of which may weaken an individual’s immune system. As a result, a frequent and serious risk of this treatment is the occurrence of severe and sometimes deadly infections.

    Omisirge, administered as a single intravenous dose, is composed of human allogeneic stem cells from umbilical cord blood that are processed and cultured with nicotinamide (a form of vitamin B3). Each dose is patient-specific, containing healthy stem cells from an allogeneic pre-screened donor, meaning it comes from a different individual rather than using the patient’s own cells. 

    The safety and effectiveness of Omisirge was supported by a randomized, multicenter study comparing transplantation of Omisirge to transplantation of umbilical cord blood, in subjects between the ages of 12 and 65 years. The study enrolled a total of 125 subjects. All subjects in the study had confirmed blood cancers. The efficacy of Omisirge was based on the amount of time needed for recovery of the subject’s neutrophils (a type of white blood cell that helps protect the body from infections) and the incidence of infections following transplantation.

    Eighty-seven percent of subjects who were randomized to receive Omisirge achieved neutrophil recovery with a median of 12 days following treatment with the product, compared to 83% of subjects who were randomized to receive umbilical cord blood transplantation and who achieved neutrophil recovery with a median of 22 days. Bacterial or fungal infections by 100 days following transplantation were seen in 39% of subjects receiving Omisirge versus 60% of subjects in the control group who received umbilical cord blood.

    Treatment with Omisirge has the potential to cause severe side effects, which must be considered in assessing the risks and benefits of using this product. Similar to all approved umbilical cord products, the label carries a Boxed Warning for infusion reactions, graft versus host disease (GvHD – a condition that occurs when donor bone marrow or stem cells attack the graft recipient), engraftment syndrome (characterized by a noninfectious fever and rash), and graft failure (occurs when new cells do not produce white blood cells, red blood cells and platelets). 

    The most common adverse reactions associated with Omisirge included infections, GvHD, and infusion reactions. Patients who receive Omisirge should be monitored for signs and symptoms of infusion reactions, GvHD, engraftment syndrome, graft failure, transmission of serious infections or rare genetic diseases from the donor cells, as well as life-long for secondary malignancies (cancers that can spread from the original site or emerge following treatment). 

    This application received Priority Review, Breakthrough Therapy and Orphan designations. 

    The FDA granted regular approval of Omisirge to Gamida Cell Ltd.
     

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.


    Inquiries

    Media:
    Carly Kempler
    (240) 672-8872
    Consumer:
    888-INFO-FDA

    Get the next $GMDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GMDA

    DatePrice TargetRatingAnalyst
    11/16/2021$14.00 → $12.00Buy
    Needham
    11/16/2021$17.00 → $15.00Outperform
    Oppenheimer
    11/1/2021$11.00Buy
    Alliance Global Partners
    More analyst ratings

    $GMDA
    SEC Filings

    See more
    • SEC Form EFFECT filed by Gamida Cell Ltd.

      EFFECT - Gamida Cell Ltd. (0001600847) (Filer)

      5/14/24 12:15:25 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Gamida Cell Ltd.

      EFFECT - Gamida Cell Ltd. (0001600847) (Filer)

      5/14/24 12:15:20 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Gamida Cell Ltd.

      EFFECT - Gamida Cell Ltd. (0001600847) (Filer)

      5/14/24 12:15:14 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GMDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

      Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential of HB-200Sean Cassidy appointed to the Board of Directors NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice Pr

      7/22/24 8:30:00 AM ET
      $ARVN
      $GMDA
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • XORTX Welcomes New Member to the Board of Directors

      CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Abigail Jenkins, a biotech industry veteran with deep experience with the commercialization of therapies for renal and cardiovascular disease, to its Board of Directors. Abigail "Abbey" L. Jenkins, M.S., is the current President and CEO of Gamida Cell (NASDAQ:GMDA) and a member of its Board of Directors. Ms. Jenkins brings over 20 years of leadership experience in the biopharmaceutical industry deliv

      4/8/24 7:30:00 AM ET
      $GMDA
      $XRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

      WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company's Board of Directors, effective April 1, 2024. Ms. Jenkins has two decades of leadership in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. "I am very pleased to welcome Abbey to the Aquestive Board of Directors. Her two decades of experience in the commercialization of pharmaceutical p

      4/1/24 8:00:00 AM ET
      $AQST
      $EBS
      $GMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $GMDA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • April 17, 2023 - FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation

      For Immediate Release: April 17, 2023 Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product is intended for use in adults and pediatric patients 12 years and older with blood cancers p

      4/17/23 1:02:15 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GMDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Gamida Cell Ltd. (Amendment)

      SC 13G/A - Gamida Cell Ltd. (0001600847) (Subject)

      4/1/24 5:49:42 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Gamida Cell Ltd. (Amendment)

      SC 13G/A - Gamida Cell Ltd. (0001600847) (Subject)

      2/14/24 2:14:47 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Gamida Cell Ltd. (Amendment)

      SC 13G/A - Gamida Cell Ltd. (0001600847) (Subject)

      2/14/24 2:08:53 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GMDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Moch Kenneth I was granted 200,000 units of Ordinary Shares, increasing direct ownership by 619% to 232,300 units (SEC Form 4)

      4 - Gamida Cell Ltd. (0001600847) (Issuer)

      2/2/24 4:55:12 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wills Stephen T was granted 200,000 units of Ordinary Shares, increasing direct ownership by 356% to 256,177 units (SEC Form 4)

      4 - Gamida Cell Ltd. (0001600847) (Issuer)

      2/2/24 4:48:32 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tomasello Shawn was granted 200,000 units of Ordinary Shares, increasing direct ownership by 476% to 241,977 units (SEC Form 4)

      4 - Gamida Cell Ltd. (0001600847) (Issuer)

      2/2/24 4:45:46 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GMDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham reiterated coverage on Gamida Cell with a new price target

      Needham reiterated coverage of Gamida Cell with a rating of Buy and set a new price target of $12.00 from $14.00 previously

      11/16/21 9:17:28 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer reiterated coverage on Gamida Cell with a new price target

      Oppenheimer reiterated coverage of Gamida Cell with a rating of Outperform and set a new price target of $15.00 from $17.00 previously

      11/16/21 8:13:09 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alliance Global Partners initiated coverage on Gamida Cell with a new price target

      Alliance Global Partners initiated coverage of Gamida Cell with a rating of Buy and set a new price target of $11.00

      11/1/21 9:03:50 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GMDA
    Financials

    Live finance-specific insights

    See more
    • Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results

      BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (NASDAQ:GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the fourth quarter and full year ended December 31, 2023 and provide an update on the company on Wednesday, March 27, 2024. Following the release, management will host a conference call and live webcast at 8:30 AM Eastern Time to discuss the financial results and provide a business update. Conference Call Dial-In & Webcast Information: Date/Time:Wednesday, March 27, 2024 at 8:30 AM Eastern TimeDomestic:1-877-425-9470International:1-201-389-0878Conference ID:13744446Call

      3/22/24 8:00:00 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gamida Cell to Report Third Quarter 2023 Financial Results

      BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (NASDAQ:GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the third quarter ended September 30, 2023 and provide an update on the company on Tuesday, November 14, 2023. Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide business updates and answer questions. Conference Call Dial-In & Webcast Information:  Date/Time:Tuesday, November 14, 2023 at 8:30 AM Eastern Time Domestic:1-877-425-9470 International:1-201-389-0878 Conference ID:13741

      11/1/23 8:00:00 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gamida Cell to Report Second Quarter 2023 Financial Results

      Conference Call and Webcast Scheduled for Monday, August 14th at 8:30 am Eastern Time Gamida Cell Ltd. (NASDAQ:GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the second quarter ended June 30, 2023 on Monday, August 14, 2023. Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates and answer questions. To access the conference call by phone, please register here and be advised to do so at least 10 minutes prior to joining. A live webcast of the conference call can be accessed b

      8/1/23 8:00:00 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GMDA
    Leadership Updates

    Live Leadership Updates

    See more
    • HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

      Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential of HB-200Sean Cassidy appointed to the Board of Directors NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice Pr

      7/22/24 8:30:00 AM ET
      $ARVN
      $GMDA
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • XORTX Welcomes New Member to the Board of Directors

      CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Abigail Jenkins, a biotech industry veteran with deep experience with the commercialization of therapies for renal and cardiovascular disease, to its Board of Directors. Abigail "Abbey" L. Jenkins, M.S., is the current President and CEO of Gamida Cell (NASDAQ:GMDA) and a member of its Board of Directors. Ms. Jenkins brings over 20 years of leadership experience in the biopharmaceutical industry deliv

      4/8/24 7:30:00 AM ET
      $GMDA
      $XRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

      WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company's Board of Directors, effective April 1, 2024. Ms. Jenkins has two decades of leadership in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. "I am very pleased to welcome Abbey to the Aquestive Board of Directors. Her two decades of experience in the commercialization of pharmaceutical p

      4/1/24 8:00:00 AM ET
      $AQST
      $EBS
      $GMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)